Involuntary orgasm
Medical research shows that the genital reflex is also regulated by the spinal cord, and not necessarily under conscious control.An involuntary orgasm may occur as the result of sexual assault or rape, which may result in feelings of shame caused by internalization of victim-blaming attitudes. The incidence of those who experience unsolicited sexual contact and experience orgasm is very low, though possibly under-reported due to shame or embarrassment of the victim. Such orgasms may happen to either gender.An unwanted orgasm may arise from a persistent genital arousal disorder. In consensual BDSM play, forced orgasm may be practised to exercise orgasm control. Tantric sex
Tantric sex, which is not the same as Buddhist tantra (Vajrayana), is the ancient Indian spiritual tradition of sexual practices. It attributes a different value to orgasm than traditional cultural approaches to sexuality. Some practitioners of tantric sex aim to eliminate orgasm from sexual intercourse by remaining for a long time in the pre-orgasmic and non-emission state. Advocates of this, such as Rajneesh, claim that it eventually causes orgasmic feelings to spread out to all of ones conscious experience.Advocates of tantric and neotantric sex who claim that Western culture focuses too much on the goal of climactic orgasm, which reduces the ability to have intense pleasure during other moments of the sexual experience, suggest that eliminating this enables a richer, fuller and more intense connection. Literature
Orgasm has been widely described in literature over the centuries.
Patients were randomized 2:1 to fostamatinib (100 mg orally twice daily) or placebo twice daily for 24 weeks. Dose could be escalated to 150 mg orally twice daily after one month. The benefit of fostamatinib was assessed based on the percentage of participants who achieved and maintained the pre-determined platelet count between treatment weeks 14 to 24 in fostamatinib and placebo groups respectively. The FIT-1 trial was conducted at 35 sites in Australia, Canada, Denmark, Hungary, Italy, Netherlands, the United Kingdom, and the United States. The FIT-2 trial was conducted at 23 sites in Austria, Bulgaria, Czech Republic, Germany, Norway, Poland, Romania, and Spain.The FDA granted the application for fostamatinib an orphan drug designation and granted the approval of Tavalisse to Rigel Pharmaceuticals.Fostamatinib was approved for medical use in the European Union in January 2020. References
External links
"Fostamatinib". Drug Information Portal. U.S. National Library of Medicine. "Fostamatinib disodium". Drug Information Portal. U.S. National Library of Medicine. Clinical trial number NCT02076399 for "A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) (FIT)" at ClinicalTrials.gov